OncoMatch/Clinical Trials/NCT06170710

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Is NCT06170710 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Anti-PD-1 monoclonal antibody for head and neck squamous cell carcinoma.

Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06170710Data as of May 2026

Treatment: Anti-PD-1 monoclonal antibody — This trial aims to evaluate whether the addition of anti-PD-1 antibody to adjuvant postoperative chemoradiotherapy could improve disease free survival in patients with high-risk locally advanced head and neck squamous cell carcinoma (HNSCC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Biomarker criteria

Required: PD-L1 (CD274) cps > 1 (cps > 1)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: anti-pd-1/pd-l1 therapy

Lab requirements

Blood counts

Adequate organ function

Kidney function

Adequate organ function

Liver function

Adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify